GigaGen’s Cali lab upgrade for antibody discovery

By Flora Southey

- Last updated on GMT


Related tags Immune system

GigaGen has relocated laboratory and office space in San Francisco to boost development of antibody therapeutics for patients with immune dysregulation.

The firm focuses on oncology antibody drug combinations, and is developing recombinant polyclonal therapies in collaboration​ with Grifols.

Half of the 15,000 sq. ft. facility – located at One Tower Place in south San Francisco – is dedicated to laboratory space, where GigaGen will house its antibody discovery platform.

This will enable the company to clone and scale drug products for all stages of preclinical development, a spokesperson told us, adding, “clinical manufacturing will be done outside of this lab space.”

In the labs – which have small-scale upstream and downstream capabilities – GigaGen “will be discovering and developing antibody therapies against disease of immune dysregulation including cancer and primary immune deficiency,” ​said the spokesperson.

The lab was designed and laid out by GigaGen’s internal R&D team, and construction and fitting was done in coordination with firms Phase 3 and The Core Group.

The other half of the site serves as office space, and will accommodate the firm’s hiring plans “for 2018 and beyond,” ​details of which were not disclosed.

Related news

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers